BIOCHIP LABS, INC.
Cleveland, OH · Medtech · Private
OcclusionChip, a microfluidic assay device that measures microvascular occlusion caused by red blood cells in sickle cell disease and other blood disorders
- Grants
- $5.7M
- 10 awards
- Sector median: 1
- Raised
- —
- No Form D on record
- Contracts
- —
- No federal contracts on record
- Patents
- —
- No published records under this name
- Sector median: 2
Capital Timeline
Federal ↑Equity ↓2020202120222023202420252026
| Date | Event | Source | Amount |
|---|---|---|---|
| Federal grant | National Science Foundation · Phase I · STTR Phase I: Standardized and reproducible culture and activation of endothelial cells in microfluidic devices for drug screening applications | $256,000 | |
| Federal grant | Department of Health and Human Services · Phase I · Endothelialized microfluidic assays for emerging therapies in sickle cell disease | $256,578 | |
| Federal grant | Department of Health and Human Services · Phase II · Microfluidic Technology for Concurrent Assessment of Red Blood Cell Adhesion and Deformability | $259,611 | |
| Federal grant | Department of Health and Human Services · Phase II · Endothelialized microfluidic assays for emerging therapies in sickle cell disease | $852,121 | |
| Federal grant | Department of Health and Human Services · Phase II · Endothelialized microfluidic assays for emerging therapies in sickle cell disease | $842,828 | |
| Federal grant | Department of Health and Human Services · Phase II · Microfluidic Technology for Concurrent Assessment of Red Blood Cell Adhesion and Deformability | $936,216 | |
| Federal grant | National Science Foundation · Phase II · STTR Phase II: Optimized manufacturing and machine learning based automation of Endothelium-on-a-chip microfluidic devices for drug screening applications. | $1,085,488 | |
| Federal grant | Department of Health and Human Services · Phase II · Microfluidic Technology for Concurrent Assessment of Red Blood Cell Adhesion and Deformability | $865,375 | |
| Federal grant | Department of Health and Human Services · Phase II · Microfluidic Technology for Concurrent Assessment of Red Blood Cell Adhesion and Deformability (Administrative Supplement) | $70,840 | |
| Federal grant | Department of Health and Human Services · Phase II · Manufacturing and Analytical Validation of the Microfluidic Impedance Red Cell Assay (MIRCA) for Commercial Viability | $316,800 |
Federal grant · SBIR/STTR
Peer position
| # | Company | Contracts | Disclosed equity |
|---|---|---|---|
| 918 | C4 IMAGING, LLC | — | $6.0M |
| 919 | Granite Medical, LLC | — | — |
| 920 | LungLife AI, Inc. | — | $53M |
| 921 | BIOCHIP LABS, INC. | — | — |
| 922 | BIODTECH, INC. | — | $575K |
| 923 | Innova Vascular, Inc. | — | $22M |
| 924 | AGITATED SOLUTIONS, LLC | — | $515K |
Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.
Regulatory activity · Medtech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.